文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

表皮生长因子受体酪氨酸激酶抑制剂治疗罕见表皮生长因子受体突变的转移性非小细胞肺癌：播客。

EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.

机构信息

The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Baylor University Medical Center, Dallas, TX, USA.

出版信息

Target Oncol. 2023 Nov;18(6):807-817. doi: 10.1007/s11523-023-00994-2. Epub 2023 Oct 4.

DOI:10.1007/s11523-023-00994-2
PMID:37792237
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10663258/
Abstract

Supplementary file1 (MP4 21169 KB).

摘要

补充文件 1（MP4，21169KB）。

相似文献

[1]
EGFR Tyrosine Kinase Inhibitors for the Treatment of Metastatic Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: A Podcast.

Target Oncol. 2023-11

[2]
Correlation between the qualification for bevacizumab use and the survival of patients with non-small cell lung cancer harboring the epidermal growth factor receptor mutation: a retrospective analysis.

J Cancer Res Clin Oncol. 2019-7-26

[3]
Afatinib, an effective treatment for patient with lung squamous cell carcinoma harboring uncommon EGFR G719A and R776C co-mutations.

J Cancer Res Clin Oncol. 2022-5

[4]
Epidermal growth factor receptor tyrosine kinase (EGFR-TK) mutation testing in adults with locally advanced or metastatic non-small cell lung cancer: a systematic review and cost-effectiveness analysis.

Health Technol Assess. 2014-5

[5]
Excellent survival benefit achieved in patients with advanced-stage non-small cell lung cancer harboring the epidermal growth factor receptor-G719X mutation treated by afatinib: the real-world data from a multicenter study in Vietnam.

Ther Adv Respir Dis. 2025

[6]
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non-small-cell lung cancer and EGFR mutation.

Cochrane Database Syst Rev. 2025-5-27

[7]
Clinical outcomes of advanced non-small cell lung cancer patients harboring distinct subtypes of EGFR mutations and receiving first-line tyrosine kinase inhibitors: brain metastasis and de novo T790M matters.

BMC Cancer. 2022-2-21

[8]
Distinct Role of TP53 Co-mutations in Different EGFR Subtypes Mediating the Response to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer.

Clin Lung Cancer. 2025-9

[9]
Mutational landscape and tyrosine kinase inhibitor sensitivity in EGFR L833 and H835 mutated non-small cell lung cancer.

Cancer. 2025-9-1

[10]
A case report of a lung cancer patient with two uncommon EGFR mutations and a review of the literature: two sides of the same coin.

Anticancer Drugs. 2024-1-1

引用本文的文献

[1]
How to select between osimertinib or afatinib in P-loop and αC-helix compressing (G719X, S768I) or classical-like (L861Q) EGFR mutations: what preclinical models and clinical data have taught us in the early 2020s.

Transl Cancer Res. 2025-1-31

[2]
A Multicenter Open-Label Randomized Phase II Study of Osimertinib With and Without Ramucirumab in Tyrosine Kinase Inhibitor-Naïve -Mutant Metastatic Non-Small Cell Lung Cancer (RAMOSE trial).

J Clin Oncol. 2025-2

[3]
A Real-World Study of Patient Characteristics and Clinical Outcomes in Mutated Lung Cancer Treated with First-Line Osimertinib: Expanding the FLAURA Trial Results into Routine Clinical Practice.

Cancers (Basel). 2024-3-7

本文引用的文献

[1]
UNcommon EGFR Mutations: International Case Series on Efficacy of Osimertinib in Real-Life Practice in First-LiNe Setting (UNICORN).

J Thorac Oncol. 2023-2

[2]
Osimertinib in non-small cell lung cancer with uncommon -mutations: a subgroup analysis with pooled data from two phase II clinical trials.

Transl Lung Cancer Res. 2022-6

[3]
Dacomitinib for Advanced Non-small Cell Lung Cancer Patients Harboring Major Uncommon EGFR Alterations: A Dual-Center, Single-Arm, Ambispective Cohort Study in China.

Front Pharmacol. 2022-6-13

[4]
Non-Small Cell Lung Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology.

J Natl Compr Canc Netw. 2022-5

[5]
Systemic and Intracranial Efficacy of Osimertinib in L747P-Mutant NSCLC: Case Report.

JTO Clin Res Rep. 2022-2-15

[6]
The Lifted Veil of Uncommon EGFR Mutation p.L747P in Non-Small Cell Lung Cancer: Molecular Feature and Targeting Sensitivity to Tyrosine Kinase Inhibitors.

Front Oncol. 2022-2-11

[7]
Testing Patterns and Detection of Exon 20 Insertions in the United States.

JTO Clin Res Rep. 2022-1-25

[8]
Real-world patterns of biomarker testing and targeted therapy in de novo metastatic non-small cell lung cancer patients in the US oncology network.

Cancer Treat Res Commun. 2022

[9]
Uncommon Compound Mutations in Non-Small Cell Lung Cancer (NSCLC): A Systematic Review of Available Evidence.

Curr Oncol. 2022-1-9

[10]
Molecular Characteristics of the Uncommon EGFR Exon 21 T854A Mutation and Response to Osimertinib in Patients With Non-Small Cell Lung Cancer.

Clin Lung Cancer. 2022-6

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索